Francis J. McGovern, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 21 | 2024 | 4251 | 0.720 |
Why?
|
| Fluorides | 1 | 2019 | 134 | 0.610 |
Why?
|
| Erectile Dysfunction | 1 | 2019 | 444 | 0.500 |
Why?
|
| Carcinoma, Renal Cell | 15 | 2024 | 3163 | 0.490 |
Why?
|
| Urinary Bladder Neoplasms | 11 | 2021 | 2223 | 0.400 |
Why?
|
| Catheter Ablation | 9 | 2014 | 2751 | 0.390 |
Why?
|
| Leuprolide | 5 | 2008 | 312 | 0.370 |
Why?
|
| Nephrectomy | 5 | 2024 | 938 | 0.340 |
Why?
|
| Cystectomy | 4 | 2021 | 634 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2008 | 1520 | 0.270 |
Why?
|
| Prostatic Neoplasms | 12 | 2021 | 11101 | 0.200 |
Why?
|
| Gonadotropin-Releasing Hormone | 5 | 2008 | 1146 | 0.200 |
Why?
|
| Kidney | 3 | 2014 | 7033 | 0.200 |
Why?
|
| Nerve Transfer | 1 | 2022 | 128 | 0.180 |
Why?
|
| Salvage Therapy | 3 | 2021 | 1264 | 0.170 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2021 | 187 | 0.160 |
Why?
|
| Prostatectomy | 4 | 2016 | 1825 | 0.160 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2018 | 78 | 0.150 |
Why?
|
| Urinary Catheterization | 2 | 2009 | 193 | 0.150 |
Why?
|
| Electrons | 1 | 2019 | 265 | 0.140 |
Why?
|
| Postoperative Care | 2 | 2022 | 1468 | 0.140 |
Why?
|
| Urinary Diversion | 1 | 1997 | 134 | 0.140 |
Why?
|
| Office Visits | 1 | 2021 | 593 | 0.140 |
Why?
|
| Aorta, Abdominal | 2 | 1996 | 625 | 0.140 |
Why?
|
| Penile Neoplasms | 1 | 2018 | 161 | 0.130 |
Why?
|
| Androstenes | 1 | 2018 | 181 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2003 | 782 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 2 | 2021 | 1496 | 0.130 |
Why?
|
| Fascia | 1 | 1996 | 140 | 0.130 |
Why?
|
| Delayed Emergence from Anesthesia | 1 | 2015 | 10 | 0.130 |
Why?
|
| gamma-Cyclodextrins | 1 | 2015 | 17 | 0.130 |
Why?
|
| Androstanols | 1 | 2015 | 45 | 0.120 |
Why?
|
| Pubic Symphysis | 1 | 2014 | 20 | 0.120 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 748 | 0.120 |
Why?
|
| Prostatic Diseases | 1 | 2014 | 57 | 0.120 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2015 | 143 | 0.120 |
Why?
|
| Arteries | 1 | 2019 | 1121 | 0.110 |
Why?
|
| Prostate | 2 | 2021 | 1772 | 0.110 |
Why?
|
| Ureteral Diseases | 2 | 2008 | 63 | 0.110 |
Why?
|
| Laparoscopy | 2 | 2024 | 2035 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2022 | 2489 | 0.110 |
Why?
|
| Urinary Bladder Diseases | 1 | 1994 | 167 | 0.110 |
Why?
|
| Fistula | 1 | 2014 | 212 | 0.110 |
Why?
|
| Neuromuscular Junction | 1 | 2015 | 405 | 0.100 |
Why?
|
| Aged | 40 | 2021 | 169288 | 0.100 |
Why?
|
| Light | 1 | 1997 | 1348 | 0.100 |
Why?
|
| Priapism | 1 | 1991 | 28 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 2756 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 1784 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1996 | 951 | 0.090 |
Why?
|
| Male | 48 | 2022 | 360693 | 0.090 |
Why?
|
| Diphosphonates | 3 | 2007 | 634 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 943 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2014 | 460 | 0.090 |
Why?
|
| Posture | 1 | 2014 | 956 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 9278 | 0.080 |
Why?
|
| Urologic Surgical Procedures | 1 | 2011 | 298 | 0.080 |
Why?
|
| Postoperative Complications | 4 | 2021 | 15637 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 2009 | 142 | 0.080 |
Why?
|
| Humans | 60 | 2024 | 761208 | 0.080 |
Why?
|
| Cystoscopy | 3 | 1999 | 131 | 0.070 |
Why?
|
| Protoporphyrins | 2 | 1999 | 168 | 0.070 |
Why?
|
| Middle Aged | 33 | 2022 | 220853 | 0.070 |
Why?
|
| Diverticulitis, Colonic | 1 | 2009 | 138 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2014 | 1094 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 1996 | 1670 | 0.070 |
Why?
|
| Follow-Up Studies | 13 | 2018 | 39126 | 0.070 |
Why?
|
| Hospitals, General | 1 | 2011 | 799 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 1164 | 0.070 |
Why?
|
| Bone Density | 4 | 2007 | 3546 | 0.070 |
Why?
|
| Hypogonadism | 2 | 2001 | 798 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1996 | 1228 | 0.070 |
Why?
|
| Ablation Techniques | 1 | 2009 | 247 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 991 | 0.070 |
Why?
|
| Body Composition | 3 | 2008 | 2427 | 0.060 |
Why?
|
| Urography | 4 | 2009 | 316 | 0.060 |
Why?
|
| Aged, 80 and over | 16 | 2014 | 58952 | 0.060 |
Why?
|
| Androgen Antagonists | 2 | 2007 | 1408 | 0.060 |
Why?
|
| Endometriosis | 1 | 1994 | 870 | 0.060 |
Why?
|
| Osteoporosis | 2 | 2007 | 1604 | 0.060 |
Why?
|
| Cold Temperature | 1 | 2008 | 783 | 0.060 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 6819 | 0.060 |
Why?
|
| Device Removal | 1 | 2009 | 629 | 0.060 |
Why?
|
| Treatment Outcome | 12 | 2024 | 64681 | 0.060 |
Why?
|
| Heart Arrest | 1 | 2014 | 1513 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2022 | 5250 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 6341 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2014 | 1910 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 4 | 2011 | 3590 | 0.050 |
Why?
|
| Neoplasm Staging | 5 | 2016 | 11119 | 0.050 |
Why?
|
| Marketing of Health Services | 1 | 1983 | 150 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6585 | 0.050 |
Why?
|
| Spinal Nerves | 1 | 2022 | 90 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 8519 | 0.050 |
Why?
|
| Pyrroles | 1 | 2008 | 1124 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2011 | 3512 | 0.050 |
Why?
|
| Doxorubicin | 1 | 1988 | 2224 | 0.050 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2003 | 182 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2006 | 474 | 0.050 |
Why?
|
| Tomography, Spiral Computed | 1 | 2003 | 273 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2005 | 642 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2009 | 1003 | 0.050 |
Why?
|
| Anilides | 1 | 2004 | 411 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2011 | 2643 | 0.050 |
Why?
|
| Biopsy, Needle | 3 | 2006 | 1624 | 0.050 |
Why?
|
| Retrospective Studies | 12 | 2024 | 80674 | 0.050 |
Why?
|
| Imidazoles | 1 | 2007 | 1172 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 1988 | 6124 | 0.040 |
Why?
|
| Female | 26 | 2022 | 392544 | 0.040 |
Why?
|
| Urologic Diseases | 1 | 2003 | 247 | 0.040 |
Why?
|
| Adenoma | 1 | 1991 | 2159 | 0.040 |
Why?
|
| Peritoneum | 1 | 2021 | 225 | 0.040 |
Why?
|
| Indoles | 1 | 2008 | 1830 | 0.040 |
Why?
|
| Cystitis | 2 | 1998 | 95 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 938 | 0.040 |
Why?
|
| Bone Density Conservation Agents | 1 | 2007 | 793 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 6486 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2002 | 11733 | 0.040 |
Why?
|
| Fluorescence | 2 | 1999 | 751 | 0.040 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 1998 | 80 | 0.040 |
Why?
|
| Cadaver | 1 | 2022 | 1358 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 2047 | 0.040 |
Why?
|
| Reoperation | 3 | 2012 | 4303 | 0.040 |
Why?
|
| Sexuality | 1 | 2000 | 180 | 0.040 |
Why?
|
| Aminolevulinic Acid | 1 | 1999 | 145 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2008 | 2888 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 2 | 1998 | 521 | 0.040 |
Why?
|
| Neoplasm, Residual | 3 | 2008 | 1008 | 0.040 |
Why?
|
| Quality of Life | 2 | 2018 | 13367 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 3 | 2008 | 2465 | 0.040 |
Why?
|
| Urinary Fistula | 1 | 1996 | 42 | 0.030 |
Why?
|
| Fleroxacin | 1 | 1996 | 13 | 0.030 |
Why?
|
| Electrodes | 1 | 1999 | 611 | 0.030 |
Why?
|
| Glucose | 1 | 2008 | 4342 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2022 | 1152 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2000 | 360 | 0.030 |
Why?
|
| Duodenal Diseases | 1 | 1996 | 99 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2018 | 462 | 0.030 |
Why?
|
| Time Factors | 7 | 2012 | 39957 | 0.030 |
Why?
|
| Omentum | 1 | 1996 | 167 | 0.030 |
Why?
|
| Glycopyrrolate | 1 | 2015 | 33 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2008 | 20588 | 0.030 |
Why?
|
| Bronchitis | 1 | 1996 | 196 | 0.030 |
Why?
|
| Neostigmine | 1 | 2015 | 68 | 0.030 |
Why?
|
| Tissue Adhesions | 1 | 1996 | 218 | 0.030 |
Why?
|
| Vascular Neoplasms | 1 | 1997 | 166 | 0.030 |
Why?
|
| Iliac Artery | 1 | 1996 | 343 | 0.030 |
Why?
|
| Adult | 17 | 2018 | 221119 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1998 | 927 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 1998 | 417 | 0.030 |
Why?
|
| Endosonography | 1 | 1998 | 608 | 0.030 |
Why?
|
| Prospective Studies | 7 | 2022 | 54435 | 0.030 |
Why?
|
| Anesthesia Recovery Period | 1 | 2015 | 155 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3696 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 3534 | 0.030 |
Why?
|
| Neuromuscular Blockade | 1 | 2015 | 147 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 1997 | 459 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1998 | 1642 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2005 | 13632 | 0.030 |
Why?
|
| Ultrasonography | 2 | 1999 | 5969 | 0.030 |
Why?
|
| Photosensitizing Agents | 1 | 1997 | 625 | 0.030 |
Why?
|
| Stomach | 1 | 1997 | 697 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 1996 | 319 | 0.030 |
Why?
|
| Radiography, Interventional | 3 | 2005 | 1122 | 0.030 |
Why?
|
| Prognosis | 3 | 2014 | 29687 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1998 | 1436 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1996 | 982 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12052 | 0.030 |
Why?
|
| Cisplatin | 1 | 1998 | 1652 | 0.030 |
Why?
|
| Femoral Artery | 1 | 1996 | 826 | 0.020 |
Why?
|
| Boston | 3 | 2011 | 9327 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1997 | 492 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 1077 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4851 | 0.020 |
Why?
|
| Penile Erection | 1 | 1991 | 101 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2008 | 36415 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2018 | 8642 | 0.020 |
Why?
|
| Biopsy | 2 | 2003 | 6781 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 801 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1996 | 801 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 4822 | 0.020 |
Why?
|
| Abdomen | 1 | 2015 | 1128 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2015 | 2048 | 0.020 |
Why?
|
| Sensitivity and Specificity | 5 | 2005 | 14675 | 0.020 |
Why?
|
| Colon, Sigmoid | 1 | 2009 | 124 | 0.020 |
Why?
|
| Hysterectomy | 1 | 1994 | 857 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 1996 | 983 | 0.020 |
Why?
|
| Intestines | 1 | 1997 | 1908 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 2414 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 12474 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 12976 | 0.020 |
Why?
|
| England | 1 | 2008 | 526 | 0.020 |
Why?
|
| Hydronephrosis | 1 | 2008 | 271 | 0.020 |
Why?
|
| Karyotyping | 1 | 1988 | 1172 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2000 | 3253 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 2 | 1998 | 683 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2018 | 22174 | 0.010 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2005 | 162 | 0.010 |
Why?
|
| Hospital Bed Capacity, 100 to 299 | 1 | 1983 | 11 | 0.010 |
Why?
|
| Tosyl Compounds | 1 | 2004 | 115 | 0.010 |
Why?
|
| Colectomy | 1 | 2009 | 686 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 1983 | 7865 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1988 | 1682 | 0.010 |
Why?
|
| Perfusion | 1 | 2008 | 1390 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1838 | 0.010 |
Why?
|
| Bone Remodeling | 1 | 2007 | 583 | 0.010 |
Why?
|
| Lasers | 2 | 1998 | 952 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1988 | 1743 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10756 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 2003 | 90 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2008 | 732 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1988 | 1594 | 0.010 |
Why?
|
| Adiponectin | 1 | 2008 | 1107 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 2217 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1988 | 1767 | 0.010 |
Why?
|
| Syndrome | 1 | 2008 | 3271 | 0.010 |
Why?
|
| Hematuria | 1 | 2003 | 232 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8530 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2001 | 274 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 1610 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2015 | 12341 | 0.010 |
Why?
|
| Cell Division | 1 | 1988 | 4451 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 2827 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4246 | 0.010 |
Why?
|
| Testosterone | 1 | 1991 | 2472 | 0.010 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15308 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2005 | 1818 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10218 | 0.010 |
Why?
|
| California | 1 | 1983 | 1431 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 2392 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 2001 | 270 | 0.010 |
Why?
|
| Comorbidity | 1 | 2014 | 10516 | 0.010 |
Why?
|
| Nitriles | 1 | 2004 | 971 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2981 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1998 | 113 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2001 | 529 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 961 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 702 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1988 | 5871 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2001 | 723 | 0.010 |
Why?
|
| Colon | 1 | 2005 | 1791 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2002 | 877 | 0.010 |
Why?
|
| Lipids | 1 | 2008 | 3331 | 0.010 |
Why?
|
| Incidence | 2 | 2006 | 21365 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3821 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 1624 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2002 | 1525 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 3584 | 0.010 |
Why?
|
| Femur | 1 | 2001 | 1308 | 0.010 |
Why?
|
| Risk Factors | 2 | 2012 | 74239 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2007 | 2046 | 0.010 |
Why?
|
| Laparotomy | 1 | 1997 | 456 | 0.010 |
Why?
|
| Cell Line | 1 | 1988 | 15545 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3952 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2003 | 2241 | 0.010 |
Why?
|
| Interprofessional Relations | 1 | 2000 | 990 | 0.010 |
Why?
|
| Rectum | 1 | 1998 | 891 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 3832 | 0.010 |
Why?
|
| Fluorine Radioisotopes | 1 | 1996 | 420 | 0.010 |
Why?
|
| Age Factors | 2 | 2001 | 18384 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1996 | 1123 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 8479 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2001 | 1876 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 2263 | 0.010 |
Why?
|
| Vitamin D Deficiency | 1 | 2001 | 1388 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 4921 | 0.010 |
Why?
|
| Neoplasms | 1 | 2000 | 22140 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2008 | 12952 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 24021 | 0.010 |
Why?
|
| Algorithms | 2 | 1998 | 14025 | 0.000 |
Why?
|
| Communication | 1 | 2000 | 3872 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7226 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2006 | 42224 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 13385 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1996 | 9319 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2001 | 26071 | 0.000 |
Why?
|
| Child | 1 | 2006 | 80152 | 0.000 |
Why?
|
| Adolescent | 1 | 2006 | 88298 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1998 | 41496 | 0.000 |
Why?
|
| Animals | 1 | 1998 | 168079 | 0.000 |
Why?
|